QCI Interpret for Oncology

Precision medicine for any cancer assay on any platform

1,017 views
May 29, 2019
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck. Valuable information can go undetected due to inadequate mining and interpretation mechanisms. These are called "knowledge blind spots" and can have significant clinical consequences. QIAGEN is the world leader in aggregating genetic disease knowledge resources. For the past 20 years, we have partnered with clinical testing labs throughout the world to manually curate genetic evidence across all human genes (23,000). N-of-One’s approach combines expert curation, the insights of oncology experts, and a proprietary technology and knowledgebase, MarkerMine™, to provide curated, high-quality, and actionable clinical interpretation of molecular tests. Join us for an informative webinar about both clinical interpretation solutions.

Interested in learning more?

Click here


Speakers: Dan Richards, Ph.D., Vice President of Biomedical Informatics at QIAGEN Sheryl Elkin, Ph.D., Chief Scientific Officer of N-of-One, Inc.Less

Related videos

QCI Interpret for Oncology

QCI Interpret One: Oncology variant interpretation just got more precise

1,025 views June 12, 2020

Competing to offer a comprehensive genomic profiling service for solid or...

QCI Interpret for Oncology

Managing multiple biomarker therapeutic development

405 views September 12, 2019

For the past two decades, the paradigm in the field has been “one biomarker,...

QCI Interpret for Oncology

FASTQ to final report: Ultra-fast workflow for CGP

371 views July 21, 2022

As our molecular knowledge of cancer continually evolves, a new era in cancer...

QCI Interpret for Oncology

Reduce your test turnaround for large cancer panels

364 views December 31, 2019

Speaker: Sheryl Elkin, CSO, QDI, QIAGEN Interested in learning more? Click here